[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100481826":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":29,"responsibleParty":47,"collaborators":19,"id":51,"slug":19,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":19,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":19,"maxAge":19,"enrollmentInfo":58,"targetDuration":19,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":19,"overallStatus":32,"whyStopped":19,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"Loyola University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Shingrix","EXPERIMENTAL","Patients 1-3 years post transplant will receive the Shingrix vaccine in standard dosing and schedule.",[13],"Drug: Shingrix",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Shingrix vaccine will be given to all eligible patients at one to three year post allogeneic stem cell transplantation.",[9],null,[21,26],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Patrick A Hagen","CONTACT","708-327-3810","patrick.hagen@lumc.edu",{"name":27,"role":23,"phone":28,"phoneExt":19,"email":19},"Mary Lee","708-327-2241",[30],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Loyola University Medical Center","RECRUITING","Maywood","Illinois","60153","United States","US",{"type":39,"coordinates":40},"Point",[41,42],-87.84312,41.8792,{"lat":42,"lon":41},[45],{"name":46,"role":23,"phone":19,"phoneExt":19,"email":19},"Patrick Hagen",{"type":48,"investigatorFullName":49,"investigatorTitle":50,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"PRINCIPAL_INVESTIGATOR","Hagen, Patrick A","Associate Professor","100481826",false,"NCT05554068","Immunogenicity of Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients","Phase II, Non-randomized, Open-label Study to Assess the Immunogenicity and Clinical Efficacy of the Recombinant Zoster Vaccine for Recipients of an Allogeneic Hematopoietic Stem Cell Transplant","Inclusion Criteria:\n\n* Age ≥18 years\n* ≥ 12 months and ≤ 36 months post-AlloSCT\n* Donor sources: matched related, matched unrelated, cord blood\n* Any malignant hematological disease including acute leukemia, myelodysplastic syndrome, non-Hodgkin's lymphoma, Hodgkin's lymphoma, chronic lymphocytic leukemia, chronic myeloid leukemia, multiple myeloma, and myeloproliferative disorders.\n* Any conditioning regimen\n* Any planned immunosuppressive prophylactic regimen\n* Patients with chronic graft-versus-host disease on stable immunosuppression\n* Ability to understand and the willingness to sign a written informed consent.\n* Negative pregnancy test in female patients of childbearing potential\n\nExclusion Criteria:\n\n* Patients who had zoster after an allogeneic transplant and prior to enrollment\n* Patients who are currently pregnant\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to the recombinant zoster vaccine, Shingrix, or other agents used in study.\n* Patients who have had a relapse of their primary hematological disease\n* Previous allogeneic stem cell transplantation\n* Acute disease at the time of vaccination\n* Thrombocytopenia that in the judgment of the investigator would make intramuscular injection unsafe.","ALL",{"count":59,"type":60},100,"ESTIMATED","INTERVENTIONAL",[63],"PHASE2","This is a phase II study that will examine the immunogenicity of the Shingrix vaccine in patients following an allogeneic stem cell transplant.",[66],"Shingles","2023-03-07",{"date":69,"type":70},"2023-03-08","ACTUAL",{"date":67,"type":70},{"date":73,"type":60},"2026-11-01",{"name":5,"class":6},1]